EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Granulocyte-macrophage colony-stimulating factor (GM-CSF) in inflammatory lung diseases: pathogenic contributor and therapeutic target

Muhammad Afzal, Sami I. Alzarea, Imran Kazmi, Abida Khan, Surya Nath Pandey, Arcot Rekha, Rakhi Mishra, Deepika Raina, Jyoti Maithani Kalra, Kapil Kalra, Gaurav Gupta, Md Sadique Hussain

EXCLI Journal · 22.10.2026 · 25 · 1588-1633

DOI: 10.17179/excli2026-9692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EXCLI Journal, online erschienen am 22.10.2026. Verfasst von Muhammad Afzal und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is an integral pathogenic factor in inflammatory lung pathologies including asthma, COPD, and lung cancer. As a pro-inflammatory cytokine, GM-CSF triggers the division and stimulation of granulocytes and macrophages, exacerbating the inflammatory response and promoting lung tissue damage. GM-CSF is an essential factor in promoting the production of the corresponding cytokines, levelling the effect of local activity by stimulating the infiltration of immune cells and maintaining chronic inflammation. Therefore, its neutralization in many ways leads to the cessation of the progression and exacerbation of inflammation in the lungs of patients with corresponding pathologies. Inhibitory therapy associated with GM-CSF reduces the number of immune cells and activates them at the inflammatory focus. The use of neutralizing antibodies to treat an acute inflammatory process is promising because they relatively quickly neutralize the effect of pathogenic GM-CSF. However, the immunocyte response can also be inhibited at the level of formation. Therapy with GM-CSF inhibitors can significantly reduce acute inflammation but can lead to adverse changes in the innate immunity of the patient. This review highlights GM-CSF's dual function of GM-CSF as a pathogenic contributor and possible treatment targets.

Zitieren

APA

Afzal, M., Alzarea, S. I., Kazmi, I., Khan, A., Pandey, S. N., Rekha, A., Mishra, R., Raina, D., Kalra, J. M., Kalra, K., Gupta, G., & Hussain, M. S. (2026). Granulocyte-macrophage colony-stimulating factor (GM-CSF) in inflammatory lung diseases: pathogenic contributor and therapeutic target. EXCLI Journal, 25, 1588-1633. https://doi.org/10.17179/excli2026-9692

Vancouver

Afzal M, Alzarea SI, Kazmi I, Khan A, Pandey SN, Rekha A, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in inflammatory lung diseases: pathogenic contributor and therapeutic target. EXCLI Journal. 2026;25:1588-1633. doi:10.17179/excli2026-9692

BibTeX
@article{Afzal2026,
  author = {Afzal, Muhammad and Alzarea, Sami I. and Kazmi, Imran and Khan, Abida and Pandey, Surya Nath and Rekha, Arcot and Mishra, Rakhi and Raina, Deepika and Kalra, Jyoti Maithani and Kalra, Kapil and Gupta, Gaurav and Hussain, Md Sadique},
  title = {Granulocyte-macrophage colony-stimulating factor (GM-CSF) in inflammatory lung diseases: pathogenic contributor and therapeutic target},
  journal = {EXCLI Journal},
  year = {2026},
  volume = {25},
  pages = {1588--1633},
  doi = {10.17179/excli2026-9692}
}
Kostenlos starten →